Literature DB >> 19584729

Pathogenesis of kidney disease in systemic lupus erythematosus.

Harini Bagavant1, Shu Man Fu.   

Abstract

PURPOSE OF REVIEW: A combination of systemic autoimmunity and tissue response to immune injury underlie renal involvement in lupus erythematosus. In this review, we discuss recent literature investigating pathogenetic mechanisms of lupus glomerulonephritis. RECENT
FINDINGS: In lupus glomerulonephritis, glomerular immune complexes were believed to be the primary mediators of renal disease. Recent studies make it apparent that autoantibodies of multiple specificities participate in the formation of immune complexes, deposited in the kidneys. Renal infiltration by T cells, macrophages, and dendritic cells have a dominant role in the progression of lupus glomerulonephritis leading to renal failure. Activation of Toll-like receptors modulates autoantibody production and systemic interferon responses. However, glomerular cell responses to immune injury influence disease outcome. In addition, new insights on the genetics of susceptibility to end-organ damage in lupus glomerulonephritis have been discovered. Differential glomerular responses reflected in gene expression profiles during disease progression provide potential markers for diagnosis of lupus glomerulonephritis progression and flares. In addition, studies of end-organ responses provide new targets for therapeutic interventions.
SUMMARY: Lupus glomerulonephritis is a prototype of immune complex disease mediated by autoantibodies of multiple specificities, one of which is anti-DNA. Murine models of spontaneous systemic lupus erythematosus have been critical for understanding the underlying disease. Recent studies demonstrate that in addition to systemic autoimmunity, end-organ responses, and end-organ resistance to damage are also critical in determining disease outcome. This understanding should influence design of novel therapeutic approaches in systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584729      PMCID: PMC2841319          DOI: 10.1097/BOR.0b013e32832efff1

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  41 in total

1.  Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain.

Authors:  Chun Xie; Xin J Zhou; Xuebin Liu; Chandra Mohan
Journal:  Arthritis Rheum       Date:  2003-04

2.  Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies.

Authors:  Bisram Deocharan; Xiaoping Qing; Juan Lichauco; Chaim Putterman
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

3.  Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis.

Authors:  Guillermo Pérez DE Lema; Holger Maier; Elena Nieto; Volker Vielhauer; Bruno Luckow; Francisco Mampaso; Detlef Schlöndorff
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

4.  NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci.

Authors:  S T Waters; S M Fu; F Gaskin; U S Deshmukh; S S Sung; C C Kannapell; K S Tung; S B McEwen; M McDuffie
Journal:  Clin Immunol       Date:  2001-09       Impact factor: 3.969

5.  Strain distribution pattern of susceptibility to immune-mediated nephritis.

Authors:  Chun Xie; Ruchi Sharma; Hongwei Wang; Xin J Zhou; Chandra Mohan
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

6.  Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus.

Authors:  Mart Mannik; Cynthia E Merrill; Louis D Stamps; Mark H Wener
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

7.  Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury.

Authors:  Felix Heymann; Catherine Meyer-Schwesinger; Emma E Hamilton-Williams; Linda Hammerich; Ulf Panzer; Sylvia Kaden; Susan E Quaggin; Jürgen Floege; Hermann-Josef Gröne; Christian Kurts
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

8.  An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.

Authors:  Deijanira Alves De Albuquerque; Vijay Saxena; David E Adams; Gregory P Boivin; Hermine I Brunner; David P Witte; Ram Raj Singh
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612

9.  Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.

Authors:  Lena Schiffer; Jayashree Sinha; Xiaobo Wang; Weiqing Huang; Gero von Gersdorff; Mario Schiffer; Michael P Madaio; Anne Davidson; Gero Von Gonsdorff
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

10.  Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis.

Authors:  Samuel T Waters; Marcia McDuffie; Harini Bagavant; Umesh S Deshmukh; Felicia Gaskin; Chao Jiang; Kenneth S K Tung; Shu Man Fu
Journal:  J Exp Med       Date:  2004-01-12       Impact factor: 14.307

View more
  59 in total

1.  Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7-dependent lupus.

Authors:  Yudong Liu; Yaíma L Lightfoot; Nickie Seto; Carmelo Carmona-Rivera; Erica Moore; Rishi Goel; Liam O'Neil; Pragnesh Mistry; Victoria Hoffmann; Santanu Mondal; Padmavathy Nandha Premnath; Katherine Gribbons; Stefania Dell'Orso; Kan Jiang; Paul R Thompson; Hong-Wei Sun; Scott A Coonrod; Mariana J Kaplan
Journal:  JCI Insight       Date:  2018-12-06

2.  Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens.

Authors:  Maurizio Bruschi; Maricla Galetti; Renato Alberto Sinico; Gabriella Moroni; Alice Bonanni; Antonella Radice; Angela Tincani; Federico Pratesi; Paola Migliorini; Corrado Murtas; Franco Franceschini; Barbara Trezzi; Francesca Brunini; Rita Gatti; Regina Tardanico; Giancarlo Barbano; Giorgio Piaggio; Piergiorgio Messa; Pietro Ravani; Francesco Scolari; Giovanni Candiano; Alberto Martini; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2014-11-14       Impact factor: 10.121

3.  Human platelet FcγRIIA and phagocytes in immune-complex clearance.

Authors:  Zhen-Yu Huang; Paul Chien; Zena K Indik; Alan D Schreiber
Journal:  Mol Immunol       Date:  2010-12-17       Impact factor: 4.407

4.  Urinary expression of long non-coding RNA TUG1 in non-diabetic patients with glomerulonephritides.

Authors:  Fernando Javier Salazar-Torres; Miguel Medina-Perez; Zesergio Melo; Claudia Mendoza-Cerpa; Raquel Echavarria
Journal:  Biomed Rep       Date:  2020-11-20

5.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

6.  TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.

Authors:  Sonya J Wolf; Jonathan Theros; Tammi J Reed; Jianhua Liu; Irina L Grigorova; Giovanny Martínez-Colón; Chaim O Jacob; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2018-06-08       Impact factor: 5.422

7.  Methyl-CpG-Binding Protein 2 (MECP2) Polymorphism in Iranian Patients with Systemic Lupus Erythematosus.

Authors:  Samira Alesaeidi; Jafar Karami; Mahdi Mahmoudi; Mahmoud Akbarian; Shiva Poursani; Azadeh Amirzadeh; Nazgol-Sadat Haddadi; Elahe Saffari; Ahmad Reza Jamshidi
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

8.  Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.

Authors:  Sun-Sang J Sung; Yan Ge; Chao Dai; Hongyang Wang; Shu Man Fu; Rahul Sharma; Young S Hahn; Jing Yu; Thu H Le; Mark D Okusa; Warren K Bolton; Jessica R Lawler
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

Review 9.  B-cell depletion in the treatment of lupus nephritis.

Authors:  Jon W Gregersen; David R W Jayne
Journal:  Nat Rev Nephrol       Date:  2012-07-17       Impact factor: 28.314

10.  Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes.

Authors:  N Yaghini; M Mahmoodi; Gh R Asadikaram; Gh H Hassanshahi; H Khoramdelazad; M Kazemi Arababadi
Journal:  Iran Red Crescent Med J       Date:  2011-10-01       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.